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Smith et al. (2010) establish a humanizedmousemodel of latent host and cellular tropism of human cytomeg-
alovirus (HCMV) infection and examine the effects of granulocyte-colony stimulating factor (GCSF) on human
cytomegalovirus (HCMV) reactivation in vivo. HCMV-infected circulating CD34+ myeloid cells populate end
organs such as the liver and differentiate into cells capable of supporting lytic infection.The exquisite host and cellular tropism of
human cytomegalovirus (HCMV) has
restricted most studies of HCMV latency
to in vitro systems in which exogenous
virus infection is used to generate latently
infected cells. Although informative, these
in vitro systems rely on the recapitulation
of conditions of virus infection and cellular
differentiation that take place in vivo,
many of which remain undefined. Primi-
tive models using SCID mice grafted
with human tissue explants have been
used previously for studies of latency
in vivo but have provided little, if any,
data that have extended results from
in vitro systems. In contrast to models
utilizing SCID mice, the model described
by Smith et al. in this issue of Cell Host &
Microbe represents a significant advance
in the study of HCMV latency and will
enable investigators to address funda-
mental questions surrounding HCMV
latency and reactivation in an in vivo
system that more closely mimics human
infection (Smith et al., 2010).
HCMV infection is ubiquitous with rates
of infection reaching 60% by adulthood.
As with other herpesviruses, it establishes
life-long persistence. Rarely does HCMV
infection result in clinical disease in
normal hosts, but is a major cause of
disease in immunocompromised hosts,
including recipients of solid organ or
hematopoietic allografts. Sources of
HCMV infection in these patients include
transplanted organs from HCMV infected
donors, infected blood products, and
reactivation of latent infection in graftrecipients. Early studies demonstrated
that HCMV could be transmitted by blood
transfusions, presumably by leukocytes
within the blood products. HCMV DNA
was detected in peripheral blood mono-
cytes leading to the hypothesis that virus
from infected monocytes transmitted
HCMV to recipients of blood products
(Schrier et al., 1985). The frequency of
HCMV DNA containing mononuclear cells
in peripheral blood has been shown to be
vanishingly low, ranging from 0.01%–
0.004%, thus raising questions about the
biological importance of virus infected
cells in the transmission of HCMV (Slo-
bedman and Mocarski, 1999). Moreover,
the recovery of infectious HCMV from
peripheral blood monocytes remained
elusive until 1997 when infectious virus
was recovered from monocytes from in-
fected donors that were differentiated
in vitro into macrophages and dendritic
cells (Soderberg-Naucler et al., 1997).
Other laboratories demonstrated HCMV
DNA in cells of the myeloid lineage
(CD14+ and CD33+) as well as in CD34+
progenitor cells (Goodrum et al., 2004;
Mendelson et al., 1996). A concept that
evolved from these and related studies
is that HCMV persists as a latent infection
in CD34+ progenitor cells, and differentia-
tion of these progenitors into cells of
myeloid lineage is associated with
HCMV reactivation and lytic replication.
The phenotype of the cell(s) within the
CD34+ progenitor cell population in which
HCMV persists remains undefined, as
CD34 is expressed by a heterogenousCell Host & Microbe 8, Sepopulation of cells. Results from studies
utilizing in vitro infection of bone marrow
cells and additional markers such as
CD38 and c-kit to refine the phenotype
of infected CD34+ cells during lineage
specific differentiation argued that
HCMV was maintained as a latent infec-
tion with restricted viral gene expression
in CD34+/CD38- cells (Goodrum et al.,
2004). These investigators also sug-
gested that productive viral replication
occurred in a subpopulation ofmore prim-
itive CD34+/CD38-/lin-/Thy1+ cells within
the CD34+ population and that infection
of CD34+/CD38+ c-kit+ cells committed
to a specific lineage ended in abortive
infections (Goodrum et al., 2004). These
findings appeared at odds with the para-
digm that lytic infection occurs in more
differentiated myeloid cells and raised
the possibility that HCMV reactivation
occurred only in differentiated cells of
specific lineages under conditions that
could not be reproduced under these
in vitro conditions. This latter experi-
mental hurdle is inherent to in vitro
systems dependent on reconstitution of
culture conditions that support cell sur-
vival, proliferation, and differentiation of
myeloid progenitor cells under the con-
straints of an in vivo environment. Such
technical issues can now be overcome
using the model presented by Smith
et al. Myeloid cells can be analyzed at
various stages of differentiation post-
bone-marrow mobilization for the pres-
ence of viral DNA and RNA, and the
requirement for specific cytokines and/orptember 16, 2010 ª2010 Elsevier Inc. 223
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sary for viral reactivation can be interro-
gated systematically. In this model, the
impact of the adaptive immune system
and the innate NK response upon viral
reactivation have been eliminated,
permitting in vivo analysis of myeloid
differentiation and HCMV reactivation
independent of these responses.
HCMV latency within CD34+ progenitor
cells is associated with restricted viral
gene expression followed by a switch to
widespread transcription of viral genes
during reactivation, including late viral
genes characteristic of lytic infection.
Candidate latency associated viral tran-
scripts have been described, but their
role in latency is unclear, and most are
detected during lytic replication in fibro-
blasts. Two recently described latency
associated transcripts, UL138 and
UL81-82 (LUNA), have been detected in
HCMV infected CD34+ progenitor cells
and during lytic infection (Bego et al.,
2005; Goodrum et al., 2007; Reeves
et al., 2010). In contrast to previously
described transcripts associated with
HCMV latency, more convincing argu-
ments for the potential roles of both
UL138 and UL81-82 in latency have
been proposed (Bego et al., 2005; Good-
rum et al., 2007; Reeves et al., 2010).
Latency and restricted viral gene expres-
sion in progenitor cells are areas of
intense investigation that have focused
on interactions between cellular and viral
functions. Several proposed mechanisms
of repression of virus reactivation are
based on restricted expression of viral
immediate early genes that initiate the
cascade of viral gene expression during
virus replication. These include silencing
of viral promoters possibly through his-
tone modifications and effector functions
of protein components of the nuclear
domain 10 (ND10) (Reeves et al., 2010).
Such studies have been carried out only
in vitro and thus are also prone to experi-
mental biases described above, particu-
larly in the establishment of cultures
of progenitor cells and their infection
in vitro. Experimental systems such as
that described in the current report may
provide a milieu that more closely resem-
bles that found in vivo and hopefully will224 Cell Host & Microbe 8, September 16, 20move studies of HCMV latency from
hypothesis generation to hypothesis
testing.
Reactivation of HCMV from mononu-
clear cells in immunocompromised hosts
can lead to uncontrolled virus replication,
dissemination, and end organ disease.
Mortality rates in hematopoietic allograft
recipients with disseminated HCMV
infections were nearly 90% prior to the
availability of antiviral agents, and even
with treatment HCMV infection can lead
to significant morbidity and mortality.
Further, antiviral drugs have marrow
toxicities that can limit their utilization in
the early engraftment period. Because
HCMV is not the only opportunistic path-
ogen of hematopoietic transplant recipi-
ents, strategies to improve the success
of engraftment and acceleration of graft
function have been employed, including
increasing the number of myeloid progen-
itor cells in the graft. Such strategies lead
to earlier normalization of granulocyte
numbers in the peripheral blood, poten-
tially decreasing morbidity secondary to
bacterial and fungal infections. Studies
of hematopoietic stem cell transplant
(HSCT) recipients suggested that an
increasing number of CD34+ cells in the
transplant could be correlated with more
favorable outcome in HSCT recipients,
presumably secondary to more rapid
graft function. In addition, mobilization of
CD34+ progenitor cells into the peripheral
blood with GCSF provides a ready source
of bone-marrow-derived progenitor cells
for use in hematopoietic stem cell trans-
plantation. Yet the use of GCSF is not
without potential drawbacks. Recipients
of GCSF mobilized CD34+ progenitor
cells from HCMV seropositive donors
have been reported to have about a
5-fold increase in serious HCMV infec-
tions, perhaps secondary to delayed
engraftment of the lymphoid compart-
ment in these patients (Holmberg et al.,
1999). An alternative interpretation of
these findings and one consistent with
the observations of Smith and colleagues
is that mobilization of CD34+ progenitor
cells and activation of HCMV latent infec-
tion by GCSF lead to dissemination and
clinical disease prior to functional recon-
stitution of the lymphoid compartment in10 ª2010 Elsevier Inc.these patients (Smith et al., 2010). Simi-
larly, selection of CD34+ cells from
HCMV-infected donors following treat-
ment with GCSF as a source of myeloid
progenitors could also favor HCMV reac-
tivation as shown in the Smith et al. study.
The potential of the model system
described by Smith et al. to translate
new therapeutic approaches into the
care of transplant patients can be readily
appreciated. This system could be used
to definitively identify progenitor cell
types essential for HCMV latency and
reactivation, thus permitting depletion of
such cells from hematopoietic grafts. In
addition, druggable targets could be iden-
tified, including viral gene products
essential for reactivation from latency,
host factors essential for viral reactivation,
or downstream cellular functions required
for efficient viral replication in myeloid
cells. Inhibitors of these viral or host cell
functions could also be assayed in this
animal model for evidence of efficacy as
well as potential toxicity prior to initiation
of clinical trials.REFERENCES
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